Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.

MLA

Fahrenholtz, Cale D., et al. “Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts.” Molecular Cancer Therapeutics, vol. 12, no. 4, Apr. 2013, pp. 394–404. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-12-0648.

APA

Fahrenholtz, C. D., Beltran, P. J., & Burnstein, K. L. (2013). Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Molecular Cancer Therapeutics, 12(4), 394–404. https://doi.org/10.1158/1535-7163.MCT-12-0648

Chicago

Fahrenholtz, Cale D, Pedro J Beltran, and Kerry L Burnstein. 2013. “Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts.” Molecular Cancer Therapeutics 12 (4): 394–404. doi:10.1158/1535-7163.MCT-12-0648.